Oppenheimer Lowers Capricor Therapeutics (NASDAQ:CAPR) Price Target to $22.00

Capricor Therapeutics (NASDAQ:CAPR) had its price objective lowered by Oppenheimer from $43.00 to $22.00 in a research report report published on Monday morning,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.

Other equities research analysts also recently issued reports about the company. Wall Street Zen downgraded Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. HC Wainwright reiterated a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research note on Friday, June 13th. Roth Capital reiterated a “buy” rating and set a $31.00 target price on shares of Capricor Therapeutics in a research report on Tuesday, June 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $35.57.

Capricor Therapeutics Trading Up 8.6%

Capricor Therapeutics stock opened at $10.05 on Monday. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40. The firm has a 50-day moving average price of $10.91 and a 200-day moving average price of $12.42. The firm has a market capitalization of $459.08 million, a PE ratio of -7.08 and a beta of 0.84.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.20). Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. The firm had revenue of $2.73 million during the quarter, compared to the consensus estimate of $3.16 million. During the same period in the previous year, the business earned ($0.31) EPS. As a group, sell-side analysts predict that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Capricor Therapeutics by 44.4% in the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock worth $31,420,000 after buying an additional 700,243 shares during the period. Farallon Capital Management LLC purchased a new position in shares of Capricor Therapeutics during the fourth quarter valued at $31,056,000. Geode Capital Management LLC raised its holdings in shares of Capricor Therapeutics by 37.8% in the fourth quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock valued at $12,139,000 after acquiring an additional 241,279 shares in the last quarter. Woodline Partners LP lifted its stake in Capricor Therapeutics by 15.8% in the first quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company’s stock worth $6,921,000 after acquiring an additional 99,384 shares during the period. Finally, Altium Capital Management LLC grew its holdings in Capricor Therapeutics by 150.5% during the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock worth $9,853,000 after acquiring an additional 429,000 shares in the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.